Founded by leading cardiovascular scientists, our team has the tenacity to pursue our ultimate peak – changing the treatment paradigm for heart disease, and in doing so improving and extending the lives of millions of individuals and families fighting this debilitating disease.
We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease.
We are revolutionizing the treatment of heart disease through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
LATEST NEWS
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that
Read MoreTenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Established $45 Million
Read MoreTenaya Therapeutics Announces Research Leadership Updates
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role Pediatric Cardiologist and Genetic Therapy Expert Barry J. Byrne, M.D., Ph.D., Joins Scientific Advisory Board Board Member Jin-Long Chen, Ph.D., Steps Down SOUTH SAN FRANCISCO,
Read MoreJOIN OUR TEAM
Are you ambitious, driven, energized by scientific innovation and committed to making a difference for patients suffering from heart disease? Do you value a culture grounded in science and collaboration? Our team combines deep biological insights, sophisticated drug development technologies and a boundless determination to change the future for the millions of people affected by heart disease.